Analyst Research Report Snapshot

Title:

ABLYNX - STUDY DATA MAY ELICIT A PARTNER

Price:

$10.00

Provider:

Edison Investment Research

Date:

11 Oct 2012

Pages:

8

Type:

AcrobatPDF

Companies referenced:

ABLX.BR

Available for Immediate Download
Summary:

Ablynx’s technology platform received further validation from the promising Phase II study data for ALX-0061, an anti-IL6 Nanobody for rheumatoid arthritis (RA), as well as the formation of a new collaboration with Merck & Co. ALX-0061 seems to compare favourably with Roche’s Actemra, while offering the potential for a more convenient dosing schedule. The positive trial results could attract a partner for ALX-0061 and may even help with partnering of ATN-103 if the two products can be bundled together. We have increased our valuation by €20m to €521m.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.